Panaji Journal

DelveInsight’s “Metastatic Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Metastatic Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Metastatic Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Non-Small Cell Lung Cancer Market Forecast

Some of the key facts of the Metastatic Non-Small Cell Lung Cancer Market Report: 

• The Metastatic Non-Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In November 2023, AUGTYRO (repotrectinib, BristolMyers Squibb) received approval from the US FDA for use in adults with locally advanced or metastatic ROS1-positive NSCLC, especially in instances with brain metastases.
• In October 2023, Pfizer’s BRAFTOVI + MEKTOVI combination was approved by the US FDA for the treatment of metastatic NSCLC with BRAF V600E mutation.
• On October 3, 2023, Takeda decided to voluntarily withdraw EXKIVITY from the market following the failure of a confirmatory trial.
• In October 2023, Belgian pharmaceutical firm Janssen, a subsidiary of Johnson & Johnson, has disclosed results from the Phase III MARIPOSA-2 clinical study evaluating Rybrevant (amivantamab-vmjw) treatments in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This open-label, randomized trial investigated the safety and effectiveness of two Rybrevant treatment protocols in combination with chemotherapy, administered with and without lazertinib.
• In January 2023, Novocure announced that the LUNAR study, assessing the safety and effectiveness of Tumor Treating Fields (TTFields) alongside standard treatments for stage 4 Metastatic Non-Small Cell Lung Cancer (NSCLC) after progression on or following platinum-based therapy, successfully achieved its primary goal.
• The overall number of new cases of NSCLC across the 7MM was approximately 526,800 cases in 2022, with projections indicating a rise throughout the forecast period from 2024 to 2034. Statistics suggest that the United States has the highest incidence of NSCLC, followed by Japan, Germany, and the UK.
• In the EU4 countries, Germany recorded the highest number of new cases of NSCLC, estimated at around 56,000, while Spain had the lowest incidence, with approximately 26,000 cases reported in 2022.
• Key Metastatic Non-Small Cell Lung Cancer Companies: Daiichi Sankyo/AstraZeneca, Gilead Sciences, BieGene, GlaxoSmithKline, DualityBio, Latin American Cooperative Oncology Group, Mirati Therapeutics Inc., Eli Lilly and Company, Fox Chase Cancer Center, Merck Sharp & Dohme LLC, BeiGene, NeoImmuneTech, Iovance Biotherapeutics, Inc, Sanofi, Hutchison Medipharma Limited, OncoC4, Inc., Sichuan Kelun Pharmaceutical, Arcus Biosciences, Inc., and others
• Key Metastatic Non-Small Cell Lung Cancer Therapies: DatopotamabDeruxtecan(Dato-DXd), TRODELVY, Ociperlimab, JEMPERLI, ZEJULA, DB-1305, Amivantamab, AZD2936, Adagrasib, LY3537982, Nivolumab, Pembrolizumab/Vibostolimab, Tislelizumab, efineptakin alfa, LN-145, SAR408701, Dostarlimab, Savolitinib, Gotistobart, Trastuzumab deruxtecan, SKB264, Domvanalimab, and others
• The  Non-Small Cell Lung Cancer epidemiology based on gender analyzed that males are affected more in case of PD-L1 NSCLC as compared to females.
• The Metastatic Non-Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the Metastatic Non-Small Cell Lung Cancer market dynamics.

Metastatic Non-Small Cell Lung Cancer Overview

Metastatic Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that has spread beyond the lungs to other parts of the body. NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. When the cancer cells break away from the primary tumor in the lungs and travel through the bloodstream or lymphatic system to other organs or tissues, such as the liver, bones, brain, or adrenal glands, it is referred to as metastatic NSCLC. 

Get a Free sample for the Metastatic Non-Small Cell Lung Cancer Market Report: 

https://www.delveinsight.com/report-store/metastatic-non-small-cell-lung-cancer-market

Metastatic Non-Small Cell Lung Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Metastatic Non-Small Cell Lung Cancer Epidemiology Segmentation:

The Metastatic Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Metastatic Non-Small Cell Lung Cancer
• Prevalent Cases of Metastatic Non-Small Cell Lung Cancer by severity
• Gender-specific Prevalence of Metastatic Non-Small Cell Lung Cancer
• Diagnosed Cases of Episodic and Chronic Metastatic Non-Small Cell Lung Cancer

Download the report to understand which factors are driving Metastatic Non-Small Cell Lung Cancer epidemiology trends @ Metastatic Non-Small Cell Lung Cancer Epidemiology Forecast

Metastatic Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Metastatic Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Metastatic Non-Small Cell Lung Cancer Therapies and Key Companies

• DatopotamabDeruxtecan(Dato-DXd): Daiichi Sankyo/AstraZeneca
• TRODELVY: Gilead Sciences
• Ociperlimab: BieGene
• JEMPERLI: GlaxoSmithKline
• ZEJULA: GlaxoSmithKline
• DB-1305: DualityBio
• Amivantamab: Latin American Cooperative Oncology Group
• AZD2936: AstraZeneca
• Adagrasib: Mirati Therapeutics Inc.
• LY3537982: Eli Lilly and Company
• Nivolumab: Fox Chase Cancer Center
• Pembrolizumab/Vibostolimab: Merck Sharp & Dohme LLC
• Tislelizumab: BeiGene
• efineptakin alfa: NeoImmuneTech
• LN-145: Iovance Biotherapeutics, Inc
• SAR408701: Sanofi
• Dostarlimab: GlaxoSmithKline
• Savolitinib: Hutchison Medipharma Limited
• Gotistobart: OncoC4, Inc.
• Trastuzumab deruxtecan: Daiichi Sankyo
• SKB264: Sichuan Kelun Pharmaceutical
• Domvanalimab: Arcus Biosciences, Inc.

To know more about Metastatic Non-Small Cell Lung Cancer companies working in the treatment market, visit @ Metastatic Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment

Metastatic Non-Small Cell Lung Cancer Market Strengths

• NSCLC has emerged as a target indication of interest in oncology in the last decade. The focus of most trials in NSCLC in recent years has been in the metastatic setting as monotherapy or in combination with chemotherapy and other targeted agents.

Metastatic Non-Small Cell Lung Cancer Market Opportunities

• Front-line NSCLC represents a large market,currently only being dominated by anti-PD 1 drugs and anti-PD-1 + CTx combination, leaving a significant opportunity for therapy beyond antiPD1 to deliver higher clinical benefit.

Scope of the Metastatic Non-Small Cell Lung Cancer Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Metastatic Non-Small Cell Lung Cancer Companies: Daiichi Sankyo/AstraZeneca, Gilead Sciences, BieGene, GlaxoSmithKline, DualityBio, Latin American Cooperative Oncology Group, Mirati Therapeutics Inc., Eli Lilly and Company, Fox Chase Cancer Center, Merck Sharp & Dohme LLC, BeiGene, NeoImmuneTech, Iovance Biotherapeutics, Inc, Sanofi, Hutchison Medipharma Limited, OncoC4, Inc., Sichuan Kelun Pharmaceutical, Arcus Biosciences, Inc., and others
• Key Metastatic Non-Small Cell Lung Cancer Therapies: DatopotamabDeruxtecan(Dato-DXd), TRODELVY, Ociperlimab, JEMPERLI, ZEJULA, DB-1305, Amivantamab, AZD2936, Adagrasib, LY3537982, Nivolumab, Pembrolizumab/Vibostolimab, Tislelizumab, efineptakin alfa, LN-145, SAR408701, Dostarlimab, Savolitinib, Gotistobart, Trastuzumab deruxtecan, SKB264, Domvanalimab, and others
• Metastatic Non-Small Cell Lung Cancer Therapeutic Assessment: Metastatic Non-Small Cell Lung Cancer current marketed and Metastatic Non-Small Cell Lung Cancer emerging therapies
• Metastatic Non-Small Cell Lung Cancer Market Dynamics: Metastatic Non-Small Cell Lung Cancer market drivers and Metastatic Non-Small Cell Lung Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Metastatic Non-Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic Non-Small Cell Lung Cancer Market Access and Reimbursement 

Discover more about therapies set to grab major Metastatic Non-Small Cell Lung Cancer market share @ Metastatic Non-Small Cell Lung Cancer Treatment Market

Table of Contents 

1. Metastatic Non-Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for Metastatic Non-Small Cell Lung Cancer

3. SWOT analysis of Metastatic Non-Small Cell Lung Cancer

4. Metastatic Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. Metastatic Non-Small Cell Lung Cancer Market Overview at a Glance

6. Metastatic Non-Small Cell Lung Cancer Disease Background and Overview

7. Metastatic Non-Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Non-Small Cell Lung Cancer 

9. Metastatic Non-Small Cell Lung Cancer Current Treatment and Medical Practices

10. Metastatic Non-Small Cell Lung Cancer Unmet Needs

11. Metastatic Non-Small Cell Lung Cancer Emerging Therapies

12. Metastatic Non-Small Cell Lung Cancer Market Outlook

13. Country-Wise Metastatic Non-Small Cell Lung Cancer Market Analysis (2020–2034)

14. Metastatic Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. Metastatic Non-Small Cell Lung Cancer Market Drivers

16. Metastatic Non-Small Cell Lung Cancer Market Barriers

17.  Metastatic Non-Small Cell Lung Cancer Appendix

18. Metastatic Non-Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/